Capital Access Research Equity Research & Stock Reports
- Professional research and all the latest forecasts, valuation opinions and multiples from Capital Access Research's expert analysts.
- Real-time updates from analysts following company announcements and other events.
- Near-live share prices, user-friendly dashboard, charting and company content.
06 Mar 17
Intercede Group’s core intellectual property sits at the heart of the development of global cybersecurity. Providing critical elements of Multi-Factor Authentication (MFA), the company’s addressable market is poised to expand from the historic, occupational focus to a much wider transactional basis with the clear long term potential to participate in the Internet of Things (IoT). While there have been short term timing issues with key orders, this is more representative of Intercede’s history than its prospects. We view current and prospective regulatory change within national IT infrastructures, critical organisations and financial services as the catalyst for significant revenue growth, a return to profitability and share price appreciation.
Full Year 2016 Results
03 Mar 17
GlobalData has now transitioned itself into an integrated, multi-platform provider of business data. The FY2016 results are in many respects, the first full year in the new format with GlobalData trading as one global business. At the same time as rebranding and integrating core data platform acquisitions, GlobalData has delivered double-digit organic revenue and EDITDA growth. It is now well positioned to leverage sales across a global geographic platform and continues to invest accordingly. The business is evolving rapidly but the fundamentals remain the same. The business generates significant and recurring cash returns from the provision of proprietary content to large national and international clients. It is scalable, recession-resistant and has high barriers to entry.
Full Year 2016 Results
24 Feb 17
The FY2016 results for Low & Bonar were ahead of our estimates despite the underperformance of the CTT division, which had been flagged early in the year. The other three divisions generated strong constant current profits growth, through a combination of organic revenue increase and margin improvement. There is clear evidence that strategy to focus on higher margin markets at the expense of commodity businesses, or areas in which it does not have a strong market position, is now gaining traction. The company has further potential to leverage its manufacturing expertise and intellectual property in order to expand through a combination of organic growth and selective M&A activity. The new Colback plant in China is performing well and will be expanded this year. The current rating still reflects the Group’s historic trading difficulties and the subsequent uncertainties over the new management team with a revised strategy. However, recent evidence suggests that a more optimistic view is now appropriate.
Interim Results and Initiation of Coverage
24 Aug 16
For investors who were looking for evidence that GlobalData could repeat the performance of Datamonitor before its timely sale to Informa in 2007, the recent 1H16 results will have been encouraging. Having integrated the acquisitions of significant healthcare and consumer data assets within the past year, GlobalData is now poised for strong organic growth. The model has moved on since the Datamonitor days, with most content now provided on a subscription basis via multiple channels. However, the fundamentals are much the same. The business generates significant and recurring cash returns from the provision of proprietary content to large national and international clients. It is scalable, recession resistant and has high barriers to entry.
First Half 2016 Results
01 Aug 16
The disposal of the Sports and Leisure yarns business is proof that Low & Bonar is intent on delivering its strategy to focus on higher margin markets at the expense of commodity businesses or areas in which it does not have a strong market position. The results for the first half demonstrated that there is now solid potential growth in most areas of operation as European markets continue to stabilise. The company has the potential to leverage its manufacturing expertise and intellectual property in order to expand through a combination of organic growth and selective M&A activity, The current rating is still reflecting historic trading difficulties and the subsequent uncertainties of a new management team and a revised strategy. However, there was sufficient evidence in recent results to suggest that a more optimistic view is now appropriate.
Recruitment underway to enrol 200 patients in the pivotal Phase III clinical trial for Lupuzor
11 May 16
Lupuzor - Orion, the final step before regulatory approval. Patient recruitment is anticipated to occur in up to 45 investigator sites, 10 in the United States and 35 in Europe. In the US the first patient dosing commenced in February 2016. In Europe, the first sites have opened in France and patient recruitment has commenced. The trial progress can be tracked on the www.ClinicalTrials.gov/lupuzor website and the key milestone for this year is for the recruitment of the 200 Lupus patients, with top-line results from the trial expected to be available in late 2017.
Capital Access Research Research and Daily Commentaries
Research Tree offers Capital Access Research research, providing ongoing coverage of 13 shares. We offer 19 reports from Capital Access Research on Research Tree.
Research reports provided by Capital Access Research
Companies covered by Capital Access Research
Sectors covered by Capital Access Research